- Clinical proof of concept data in 2021 anticipated across multiple programs - CAMBRIDGE, Mass. , Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined significant clinical...

- SYNB1891 demonstrates STING activation and target engagement in the tumor microenvironment in monotherapy cohorts - CAMBRIDGE, Mass. , Dec. 14, 2020 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine,...

CAMBRIDGE, Mass. , Dec. 9, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Michael Heffernan to its board of directors....

CAMBRIDGE, Mass. , Dec. 7, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present additional translational and in silico data on SYNB8802, a Synthetic Biotic medicine...

CAMBRIDGE, Mass. , Nov. 18, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of...

- Synlogic ends 3Q2020 with $102.0 million in cash, cash equivalents and investments supporting projected runway into 2022 -   - Phase 2 study of SYNB1618 and Phase 1 study of SYNB8802 initiated -   - Management to host conference call and webcast at 8:30 a.m. ET today - CAMBRIDGE, Mass. , Nov....

CAMBRIDGE, Mass. , Nov. 4, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced it has treated the first healthy volunteer in its Phase 1 study of the investigational Synthetic Biotic...

CAMBRIDGE, Mass. , Oct. 27, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its third quarter 2020 financial results before the market opens on Thursday,...

CAMBRIDGE, Mass. , Oct. 22, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present a poster on SYNB8802, an investigational Synthetic Biotic medicine for the treatment...

CAMBRIDGE, Mass. , Sept. 14, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of David Hava , Ph.D. as Chief Scientific Officer. Dr....

CAMBRIDGE, Mass. , Sept. 8, 2020 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's president and chief executive officer, and other members of...

- Synlogic ends 2Q2020 with $109.1 million in cash, cash equivalents and investments supporting projected runway into 2022 - Company continues to advance multiple clinical stage Synthetic Biotic medicines - Management to host conference call and webcast at 8:00 am ET today - CAMBRIDGE,...